Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Prana Biotechnology — Shareholder Meeting (November 2017)
8 slides from Alterity Therapeutics's shareholder meeting presentation, Nov 17, 2017
Slide 1: Treatment of Neurological Disorders
Treatment of Neurological Disorders David Stamler, M.D. AGM 2017
Slide 2: Highlights
Highlights 2 NOVEL DRUG CANDIDATE: PBT434 ▪ Targets key protein implicated in neurodegeneration of Parkinson’s disease and atypical parkinsonism ▪ Prevents accumulation and aggregation of α - synuclein ▪ Well tolerated in repeated dose toxicology studies STRONG RESEARCH AND DEVELOPMENT ▪ Innovative
Slide 3: Rapidly Growing Burden of Neurological Disease based on Aging Population
Rapidly Growing Burden of Neurological Disease based on Aging Population 3 “Because the incidence of PD increases sharply with age and because the world’s population is aging, the number of individuals affected is poised for exponential growth.” Dorsey, Bloem . JAMA Neurology Published online Novemb
Slide 4: PBT434 – Strong Development Rationale
PBT434 – Strong Development Rationale • PBT434 is a 2 nd generation drug to emerge from Prana’s research program • Distinct chemical scaffold and biological profile compared to prior drug candidates • Excellent drug candidate based on physical characteristics • PBT434 targets α - synuclein, a biolog
Slide 5: α-Synuclein is an Important Disease Target
α - Synuclein is an Important Disease Target Strong Genetic and Pathological Link to Disease 5 “Collectively these data strongly suggest that alpha synuclein is a potentially important and novel target of candidate neuroprotective therapies. Several different therapeutic strategies designed to clear
Slide 6: PBT434 Lowers α-Synuclein and Prevents Neuronal Death
PBT434 Lowers α - Synuclein and Prevents Neuronal Death Transgenic Animal Model ( hA53T) of PD 6 Preserves neurons in S. nigra T o t a l S N p c n e u r o n s W/T Vehicle PBT434 0 4000 8000 ** Treatment • 4 - 8 months of age • ~30 mg/kg/day (via feed) ↓ α - Synuclein aggregation h A 5 3 T - - s y n
Slide 7: Strategy Supported by Proof of Concept with Deferiprone
Strategy Supported by Proof of Concept with Deferiprone 6 month placebo controlled data in Parkinson’s disease patients 7 S. nigra Brain Iron by MRI Motor Function – UPDRS III Devos et al. Antiox . and Redox Signaling. 2014; 21: 195 DFP PBO DFP PBO S. nigra Improvement DFP Fe binding Affinity Kb =10
Slide 8: Summary
Summary • PBT434 targets α - synuclein, a biologically important protein implicated in neurodegenerative diseases • Iron is increased in the brain of patients with target diseases • PBT434 restores iron homeostasis and blocks the accumulation and aggregation of this protein • PBT434 has shown clear
Prana Biotechnology — Shareholder Meeting (November 2017) on 6ix